Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...